摘要
Objectives: To investigate the efficacy and safety of oral semaglutide 7 and 14 mg, the only orally delivered glucagon-like peptide-1 (GLP-1) receptor agonist tablet approved for type 2 diabetes mellitus (T2DM) patients. Methods: Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM from inception through May 31, 2021. The primary outcomes included change from baseline in hemo-globin A1c (HbA1c) and body weight. Risk ratios (RR), mean differences (MD), and 95% confidence intervals (CI) were calculated to evaluate the outcomes. Results: This meta-analysis included 11 RCTs with a total of 9821 patients. Compared with placebo, semaglutide 7 and 14 mg reduced HbA1c by 1.06% (95% CI, 0.81-1.30) and 1.10% (95% CI, 0.88-1.31), respectively. While in comparison with other antidiabetic agents, semaglutide 7 and 14 mg reduced HbA1c by 0.26% (95% CI, 0.15-0.38) and 0.38% (95%CI, 0.31-0.45). Both doses of semaglutide could significantly reduce body weight. Semaglutide 14 mg did increase the incidence of medication discontinuation and gastrointestinal events (nausea, vomiting and diarrhea). Conclusion: Once-daily semaglutide 7 and 14 mg can significantly lowered HbA1c and body weight in patients with T2DM, and this effect increases with dose. Significantly, more gastrointestinal events occurred with sem-aglutide 14 mg.
学科与关键词
- Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic reviewXie, Zeyu; Hu, Jia; Gu, Hangye; Li, Mengting; Chen, Jisheng*Frontiers in Endocrinology, 2023, 14: 1244432.被引 1
- Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic ReviewXie, Zeyu; Yang, Sensen; Deng, Weishang; Li, Jinjian; Chen, Jisheng*Clinical Epidemiology, 2022, 14: 1463-1476.被引 8
- Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysisZhong, Ping; Zeng, Hai; Huang, Miaochun; Fu, Wenbin*; Chen, Zhixia*ENDOCRINE, 2022, 75(3): 718-724.被引 23
